
The Evolution of Drug Therapy in Oncology - Recent Advances in Cancer Drug Therapy
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes
The number of drugs and label updates approved for cancer treatments continues to increase at a very rapid rate. In this webcast, expert faculty review recently approved therapies and relevant label updates to drug groups (chemotherapy, immunotherapy, targeted therapy) that are currently used to treat common cancers. Faculty will use case studies to illustrate treatment considerations with novel therapies. Learners will increase their knowledge of mechanism of actions, indications, and management of adverse effects associated with novel medications.
Target Audience
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
Learning Objectives
1. Discuss drugs recently approved for the treatment of cancer including the mechanism of action, current place in therapy and drug-related adverse events.
2. Identify anticancer therapies that have had relevant changes in labeling related to clinical applications and drug-related adverse events.
3. Outline treatment considerations for use of the drug therapies discussed in real-world patient cases.
Faculty
Megan Lau, PharmD, BCOP
Megan Lau, graduated from St. John Fisher College with her Doctor of Pharmacy in 2014. She completed her PGY-1 Pharmacy Practice Residency at Beth Israel Deaconess Medical Center in Boston, MA. She subsequently completed her PGY-2 Oncology Pharmacy Residency at Oregon Health & Science University (OHSU). She earned her Board Certification in Oncology Pharmacy in 2017. She has been working as a Clinical Oncology Pharmacist at OHSU since 2016. She practices across many oncology settings, including inpatient, infusion, and ambulatory clinics, with her primary focus in adult solid tumors.
DISCLOSURES:
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Megan Lau Has no relevant disclosures
Available Credit
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Price
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form.
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
DISCLOSURE OF UNLABELED USE:
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER:
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.